Key Points
- Neil Kumar, BridgeBio's CEO, sold 28,053 shares on Feb. 19 at an average price of $71.39 for proceeds of ~$2.00M, reducing his stake by 10.69% to 234,451 shares (worth ~ $16.74M).
- The Feb. 19 sale is part of a string of insider dispositions this winter — Kumar sold four earlier blocks (40,000; 40,000; 30,011; 40,000) in Dec–Feb that generated roughly $11M, bringing his recent total proceeds to about $13M across these trades.
- BridgeBio shares trade near $67.91 with a 52‑week range of $28.33–$84.94; Wall Street consensus is a “Moderate Buy” with an average price target of $82.05 (22 Buys vs. 1 Sell).
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 28,053 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $71.39, for a total transaction of $2,002,703.67. Following the completion of the transaction, the chief executive officer owned 234,451 shares in the company, valued at $16,737,456.89. The trade was a 10.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Neil Kumar also recently made the following trade(s):
- On Tuesday, February 10th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $71.94, for a total transaction of $2,877,600.00.
- On Thursday, January 8th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $73.97, for a total value of $2,958,800.00.
- On Monday, December 15th, Neil Kumar sold 30,011 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.64, for a total transaction of $2,240,021.04.
- On Thursday, December 4th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.40, for a total transaction of $2,976,000.00.
BridgeBio Pharma Stock Down 0.3%
BridgeBio Pharma stock opened at $67.91 on Tuesday. BridgeBio Pharma, Inc. has a 52-week low of $28.33 and a 52-week high of $84.94. The business has a 50-day simple moving average of $75.39 and a two-hundred day simple moving average of $64.37. The company has a market cap of $13.09 billion, a P/E ratio of -16.25 and a beta of 1.13.
Institutional Investors Weigh In On BridgeBio Pharma
Institutional investors have recently made changes to their positions in the stock. Strs Ohio increased its holdings in BridgeBio Pharma by 1.1% during the 3rd quarter. Strs Ohio now owns 18,600 shares of the company's stock worth $966,000 after purchasing an additional 200 shares in the last quarter. GAMMA Investing LLC raised its stake in BridgeBio Pharma by 28.6% in the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company's stock valued at $53,000 after purchasing an additional 227 shares in the last quarter. Steward Partners Investment Advisory LLC raised its holdings in shares of BridgeBio Pharma by 22.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company's stock worth $54,000 after buying an additional 228 shares in the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of BridgeBio Pharma by 4.9% during the fourth quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company's stock worth $396,000 after buying an additional 244 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock valued at $39,000 after buying an additional 245 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on BBIO shares. Cantor Fitzgerald upped their price target on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the stock an "overweight" rating in a research report on Thursday, October 30th. Raymond James Financial set a $89.00 price objective on BridgeBio Pharma and gave the company an "outperform" rating in a report on Thursday, February 12th. HC Wainwright increased their price target on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. TD Cowen reissued a "buy" rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Finally, The Goldman Sachs Group increased their price target on BridgeBio Pharma from $55.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, October 30th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, BridgeBio Pharma presently has an average rating of "Moderate Buy" and an average price target of $82.05.
Read Our Latest Report on BridgeBio Pharma
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
